19428-14-9
19428-14-9 结构式
基本信息
磷酸苯丙哌林
磷酸苯丙哌啉
BENPROPERINE PHOSPHATE
BENPROPERINE PHOSPHATE CP2000
1-(2-Benzylphenoxy)-2-piperidinopropane phosphate
1-[2-(2-Benzylphenoxy)-1-methylethyl]piperidine monophosphate
ASA 158-5
Blascorid
Piperidine, 1-[1-methyl-2-[(a-phenyl-o-tolyl)oxy]ethyl]-, phosphate (1:1) (8CI)
Piperidine, 1-[1-methyl-2-[2-(phenylmethyl)phenoxy]ethyl]-, phosphate (1:1)
Flaveric
物理化学性质
常见问题列表
(1) 中枢性镇咳药能够抑制延髓咳嗽中枢而产生镇咳作用，包括成瘾性镇咳药如可待因和非成瘾性镇咳药如右美沙芬、喷托维林等。
(2) 外周性镇咳药是通过抑制咳嗽反射弧中感受器、传入神经或传出神经中任何一个环节而发挥镇咳作用，如苯哌丙烷、咳快好、苯丙哌林、咳福乐、二苯哌丙烷等。
需要注意的是，镇咳药仅仅能够缓解咳嗽，但不能消除导致咳嗽的病因，只有结合病因治疗才能达到治疗的目的。无痰的干咳宜选用可待因、喷托维林或右美沙芬等药物。急性上呼吸道感染、慢性支气管炎等因素引起的咳嗽则宜选用磷酸苯丙哌林等药物。
磷酸苯丙哌林是非麻醉性镇咳药苯丙哌林的磷酸盐，外观呈白色结晶粉末，微带特臭，味苦。易溶于水、甲醇、乙酸，略溶于氯仿或苯，几乎不溶于乙醇、丙酮和乙醚。本品具有较强镇咳作用，奏效迅速，动物实验证明此药的镇咳效力比可待因强2～4倍。本品除抑制咳嗽中枢外，尚可阻断肺-胸膜的牵张感受器产生的肺-迷走神经反射，并具有罂粟碱样平滑肌解痉作用，故其镇咳作用兼具中枢性和末梢性双重机制。本品不抑制呼吸，不引起胆道及十二指肠痉挛或收缩，不引起便秘，且毒性较低，未发现耐受性及成瘾性。临床用于治疗急性支气管炎及各种原因如感染、吸烟、刺激物、过敏等引起的咳嗽，上呼吸道炎症(咽炎、鼻炎)吸烟过敏等引起的咳嗽，对刺激性干咳效佳。口服后15～60分钟内起效，持续时间为4～7小时。成人口服，每次20～40mg，1日60～120mg。也可根据病情决定。磷酸苯丙哌林副作用少，偶见口干、舌尖麻木、胃部烧灼感、食欲不振、乏力、头晕和药疹等不良反应。对本品过敏者禁用。孕妇应在医师指导下应用。
Benproperine phosphate (20-120 μM; for 24 hours) inhibits cell viability in a dose-dependent manner.
Benproperine phosphate (10 μM; for 24 hours) significantly inhibits the migration of various types of cancer cells and inhibits the migration and invasion of DLD-1, AsPC-1 cells with IC
50
values of 1-2 μM. Benproperine phosphate (10 μM; for 24 hours) does not affect cortactin-rich lamellipodium in MCF-10A cells.
Cell Viability Assay
| Cell Line: | DLD-1, AsPC-1, CFPAC-1, A375P, A375P, MDA-MB-231, DU145, DU145 cancer cells |
| Concentration: | 20, 40, 60, 80, 100, 120 μM |
| Incubation Time: | For 24 hours |
| Result: | Inhibited cell viability in a dose-dependent manner. |
Benproperine phosphate (50, 100 mg/kg; oral gavage; 5 days per week for 4 weeks) inhibits primary pancreatic tumor growth.
Benproperine phosphate shows a marked decrease in the lung metastasis of AsPC-1 cells (56.1% inhibition) in mouse. Benproperine phosphate significantly suppressed the liver metastasis of HCT-116 cells by 78.9% and DLD-1 cells by 78.2%.
| Animal Model: | Female BALB/c nude mice of 6-week-old with AsPC-1 cells |
| Dosage: | 50, 100 mg/kg |
| Administration: | Oral gavage; 5 days per week for 4 weeks |
| Result: | Inhibited primary pancreatic tumor growth compared to the vehicle control (47.7% inhibition) without body weights change. |